GSK (MEX:GSKN) ROE % Adjusted to Book Value: 8.33% (As of Mar. 2026)


MEX:GSKN GSK PLC MEX:GSKN
73 GF Score
Price MXN901.11
GF Value MXN818.82
Valuation Fairly Valued
! 1 Warning Sign
View Full Analysis

What is GSK ROE % Adjusted to Book Value?

GSK MEX:GSKN 73 ROE % Adjusted to Book Value is 8.33% as of Mar. 2026. GuruFocus rates MEX:GSKN with a GF Score™ of 73/100 and a GF Value™ of MXN818.82 (Fairly Valued). The stock has 1 warning sign investors should review.

GSK's ROE % for the quarter that ended in Mar. 2026 was 40.55%. GSK's PB Ratio for the quarter that ended in Mar. 2026 was 4.87. GSK's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 was 8.33%.

GSK ROE % Adjusted to Book Value Related Terms

GSK ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for GSK's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

GSK ROE % Adjusted to Book Value Chart

GSK Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROE % Adjusted to Book Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.35 19.46 8.88 5.70 8.31

GSK Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.55 9.27 13.61 3.51 8.33

MEX:GSKN vs LLY, JNJ, ABBV: ROE % Adjusted to Book Value Comparison

For the Drug Manufacturers - General subindustry, GSK's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

GSK ROE % Adjusted to Book Value vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, GSK's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where GSK's ROE % Adjusted to Book Value falls into.


MEX:GSKN
73GF Score
GSK PLC MEX:GSKN
ROE % Adjusted to Book Value is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

GSK ROE % Adjusted to Book Value Calculation

GSK's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=36.49% / 4.39
=8.31%

GSK's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=40.55% / 4.87
=8.33%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROE % Adjusted to Book Value of 8.33% mean?
GSK (MEX:GSKN) has a ROE % Adjusted to Book Value of 8.33% as of Mar. 2026. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on GSK and its competitors.
Is GSK's ROE % Adjusted to Book Value too high?
GSK's current ROE % Adjusted to Book Value is 8.33%. Overall, GSK has a GF Score™ of 73/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does GSK's ROE % Adjusted to Book Value compare to LLY and JNJ?
GSK's ROE % Adjusted to Book Value of 8.33% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Drug Manufacturers company?
A good ROE % Adjusted to Book Value depends on the Drug Manufacturers industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on GSK and its competitors. GSK's current ROE % Adjusted to Book Value is 8.33%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GSK stock overvalued right now?
Based on GuruFocus' analysis, GSK (MEX:GSKN) is currently considered Fairly Valued. The stock's GF Value™ is MXN818.82, compared to a current price of MXN901.11 — trading 10% above its estimated fair value. The current ROE % Adjusted to Book Value is 8.33%. GSK's overall GF Score™ is 73/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For GSK (MEX:GSKN), the current ROE % Adjusted to Book Value is 8.33% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is GSK (MEX:GSKN) Overvalued in 2026?

Based on GuruFocus' analysis, GSK stock appears to be overvalued. The current stock price of MXN901.11 is trading 10% above its estimated GF Value™ of MXN818.82. GuruFocus considers GSK to be Fairly Valued.

Key valuation signals for MEX:GSKN:

  • ROE % Adjusted to Book Value: 8.33%
  • GF Value™: MXN818.82 vs. price of MXN901.11 (10% above fair value)
  • GF Score™: 73/100 with 1 warning sign

No single metric tells the full story. See the MEX:GSKN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

GSK Business Description

Address 79 New Oxford Street, London, GBR, WC1A 1DG
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology, as well. GSK uses joint ventures to gain additional scale in certain markets like HIV.
73GF Score

Get the complete analysis for MEX:GSKN

ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN901.11
Price
MXN818.82
GF Value